Significantly Improved UPSIT Score vs Placebo at Week 24 (Key Secondary Endpoint) With Sustained Improvement Through Week 52 (Other Secondary Endpoint)3
Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.
CHANGE IN UPSIT SCORE THROUGH WEEK 52
at Week 52 with DUPIXENT
(baseline score 13.46) vs 6% worsening with placebo (baseline score 13.78) (LSM difference: 10.30 [95% CI: 8.50, 12.10])3- DUPIXENT 300 mg Q2W +
INCS (n=150) - Placebo + INCS (n=153)
Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.
change from
baseline in
UPSIT score
- 11
- 10
- 9
- 8
- 7
- 6
- 5
- 4
- 3
- 2
- 1
- 0
- -1
- -2
- 0
- 2
- 4
- 16
- 24
- 52
OF THE TOTAL
IMPROVEMENT IN SENSE OF SMELL WAS SEEN AFTER THE FIRST DOSE, AS MEASURED AT WEEK 23,bbChange in UPSIT score at Week 2 (LSM difference vs placebo: 5.36 [95% CI: 3.62, 7.10]).3
IMPROVEMENT AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (9.71 compared with a baseline score of 13.53) vs 6% worsening with placebo + INCS (n=153) (-0.81 compared with a baseline score of 13.78) (LSM difference: 10.52 [95% CI: 8.98, 12.07]) in SINUS-523
REDUCTION IN THE
NUMBER OF PATIENTS
WITH
ANOSMIA3,4
- 79% (n=228/287, pooled DUPIXENT arms) of patients taking DUPIXENT 300 mg Q2W + INCS
had anosmia at baseline, which was reduced to 30% (n=84/280, pooled DUPIXENT arms)
at Week 24 in SINUS-523,4
- There was almost no change with placebo: 76.7% (n=115/150 total patients) of patients taking placebo + INCS had anosmia at baseline, which was reduced to 76.6% (n=111/145 total patients) at Week 24 in SINUS-523,4
University of Pennsylvania Smell Identification Test (UPSIT) score (range 0 to 40): higher score indicates improvement.
Administration